Compare Amgen, Inc. (AMGN) vs Capital One Financial Corp. (COF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Capital One Financial Corp. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Capital One Financial Corp. trades at $202.02 (market cap $124.14B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | COF | |
|---|---|---|
Market Cap | $196.12B | $124.14B |
Sector | Health | Financials |
52-Week High | $388.16 | $257.94 |
52-Week Low | $271.18 | $176.10 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Capital One (COF) trades at $201.52, up 0.71% with a bearish technical signal but strong analyst support. The company reported mixed Q1 2026 earnings with a slight miss, while revenue surged to $53.43B in 2025. Key risks include subprime auto loan delinquencies and consumer credit stress, though the Discover integration offers long-term scale benefits. Technical indicators show neutral RSI readings with support at $195 and resistance at $203.
Wall Street maintains a bullish outlook with 62.5% buy ratings and a $256.25 consensus price target, representing 27% upside potential. However, declining profit margins and rising default risks in consumer lending create headwinds. The stock presents a compelling entry point for investors betting on operational improvements from recent acquisitions, though credit quality trends warrant close monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →
